Continuous Glucose Monitors for Every Budget: Accurate CGMs

Why you should trust this guide

I have spent years following the continuous glucose monitor market, analyzing clinical data, manufacturer specifications, and long-term user feedback from diabetes communities and healthcare provider reports. My focus is on separating marketing claims from real-world performance, particularly around accuracy, wearability, and system integration. I do not accept free products or sponsorships from any CGM manufacturer, and every recommendation here is based on publicly available specifications and verified user experiences.

This guide prioritizes products that have earned FDA clearance or approval for their intended use, and I have cross-referenced each device’s stated MARD (mean absolute relative difference) values with independent studies where available. I also weigh practical factors like sensor warm-up time, insertion pain reports, app reliability, and insurance coverage patterns. The five products below represent the current best in class for different use cases, from daily fingerstick replacement to fully automated closed-loop therapy.

How we researched

To evaluate these CGMs, I established a set of criteria that matter most to people managing diabetes or monitoring glucose for metabolic health. Accuracy is the primary metric, measured by MARD percentage and the sensor’s ability to track rapid glucose changes. I also assessed sensor wear time, warm-up duration, transmitter size and design, and integration with smartphones, smartwatches, and insulin pumps. Ease of insertion, skin irritation reports, and the quality of companion apps (trend graphs, alerts, data sharing) were weighted heavily.

I reviewed each product’s regulatory status, prescription requirements, and insurance coverage trends to ensure practical accessibility. For the Eversense E3, I considered the unique insertion procedure and the six-month implant lifespan. For the Dexcom Stelo, I evaluated its OTC availability and feature limitations compared to prescription models. No product was physically tested in a lab or worn by me; instead, I synthesized manufacturer documentation, clinical trial results, and aggregated user reviews from verified purchasers across multiple platforms to build a balanced picture of each device’s strengths and weaknesses.

Dexcom G7

The Dexcom G7 sets the standard for CGM accuracy with a MARD of 8.2 percent, making it one of the most precise sensors available for making insulin dosing and treatment decisions without fingerstick calibration. Its one-piece sensor and transmitter design is 60 percent smaller than the previous G6 model, and the 30-minute warm-up time is the fastest among prescription CGMs. Approved for 10-day wear, the G7 integrates seamlessly with the Dexcom G7 app, Apple Watch, Garmin watches, and multiple insulin pumps including Tandem and Omnipod systems. This universal compatibility means you can view your glucose data on nearly any device you already own, which reduces the learning curve significantly.

A major advantage is the G7’s ability to send real-time alerts for high and low glucose levels, as well as urgent low glucose alarms that can wake you during sleep. The app provides clear trend arrows, a 24-hour graph, and optional sharing with up to 10 followers. The sensor is applied with a simple one-button inserter, and the adhesive has been improved to last the full 10 days for most users. For anyone who needs the highest accuracy and broadest device integration, the G7 is the clear first choice.

A real limitation is the 10-day wear period, which means more frequent sensor changes compared to the 14-day Libre 3 or 180-day Eversense E3. Some users also report occasional adhesive irritation, though the included overpatches help. The G7 requires a prescription in most regions, which adds a step for access.

Abbott Freestyle Libre 3

The Freestyle Libre 3 is the thinnest CGM sensor on the market, roughly the size of two stacked pennies, and it streams glucose readings automatically every minute to the LibreLink app without requiring scanning. Its 14-day sensor life reduces the number of replacements per year compared to 10-day sensors, which lowers the overall cost and hassle. Accuracy is very close to the Dexcom G7 in most glucose ranges, with a MARD around 7.9 percent in clinical trials, making it reliable for daily management decisions. The app includes trend graphs, estimated A1C readings, and optional alarms for high and low glucose, adding real clinical utility for both Type 1 and Type 2 patients.

The Libre 3 is now covered by most major insurance plans, and its lower out-of-pocket cost compared to the G7 makes it a strong value pick for people who need consistent daily monitoring without breaking their budget. The sensor is applied with a simple two-piece applicator, and the small size means it is less noticeable under clothing. The system also integrates with the LibreLinkUp app for remote monitoring by caregivers or family members.

A real limitation is that the Libre 3 does not natively integrate with insulin pumps for closed-loop automation; it is primarily a standalone monitoring system. Some users find the app’s alarm customization options less flexible than Dexcom’s, and the sensor can occasionally fail before the 14-day mark, requiring a replacement request.

Medtronic Guardian 4

The Medtronic Guardian 4 is purpose-built to pair exclusively with Medtronic’s MiniMed 780G automated insulin delivery system, creating a closed-loop “artificial pancreas” that adjusts insulin delivery automatically based on real-time glucose readings. This sensor self-calibrates without fingersticks and works with the 780G’s SmartGuard technology to increase or decrease basal insulin, and even deliver automatic correction boluses, to keep glucose in range. Clinical data shows this system significantly reduces overnight hypoglycemia events and improves time-in-range compared to manual insulin dosing.

The Guardian 4 sensor lasts 7 days per application, which is shorter than many competitors, but the trade-off is the tightest possible glycemic control for people on Medtronic pumps. The sensor transmitter snaps onto the sensor and communicates wirelessly with the pump and the Medtronic mobile app. The app provides trend data, alerts, and the ability to view glucose history. For anyone already using or considering a Medtronic insulin pump, the Guardian 4 is the only sensor that unlocks full closed-loop functionality.

A real limitation is the 7-day wear time, which means more frequent sensor changes and higher supply costs. The sensor also requires a dedicated transmitter that must be charged every few days, adding another device to manage. It is not compatible with non-Medtronic pumps or standalone use, so it offers zero flexibility if you switch pump brands.

Eversense E3

The Eversense E3 takes a radically different approach to CGM: it is an implantable sensor inserted under the skin of the upper arm by a healthcare provider, and it lasts for 6 months before needing replacement. This eliminates the daily or biweekly sensor changes required by all other CGMs, which is a major advantage for people who find frequent applications burdensome or who develop skin reactions from repeated adhesive use. A removable smart transmitter worn over the implant site communicates glucose data to the Eversense app, providing real-time readings, trend arrows, and customizable alerts.

The sensor itself is tiny and resides just under the skin, so there is no visible device on the arm when the transmitter is removed for charging or showering. The transmitter vibrates on the skin for urgent low or high alerts, which is helpful for users who might miss phone alarms. The 6-month lifespan means fewer visits to the doctor for insertion and removal, and the overall annual cost can be competitive when factoring in the reduced number of sensors needed. For people with adhesive allergies or needle fatigue, the Eversense E3 is a game-changer.

A real limitation is the requirement for a healthcare provider to insert and remove the sensor, which involves a minor in-office procedure with a small incision. The transmitter must be removed and recharged daily for about 10 minutes, which can be inconvenient. Some users report mild discomfort during the first few days after insertion, and the sensor’s accuracy can be slightly lower in the first 24 hours after activation.

Dexcom Stelo

The Dexcom Stelo brings Dexcom’s proven sensor accuracy to an over-the-counter format that does not require a prescription, making it accessible to anyone interested in tracking their glucose levels. It is designed specifically for non-diabetics and Type 2 patients who are not on insulin, and it delivers 15-day sensor wear with real-time app readings and trend alerts. The Stelo uses the same underlying sensor technology as the G7, so you get reliable glucose data without the need for a doctor’s visit or prior authorization.

The app provides a clear glucose graph, daily summaries, and optional notifications for high and low readings. The 15-day wear period is longer than the G7’s 10 days, which reduces the frequency of sensor changes and lowers the per-day cost. For wellness-focused users, athletes, or people with prediabetes who want to understand how food, exercise, and sleep affect their glucose, the Stelo offers a straightforward entry point into CGM technology without the complexity of prescription devices.

A real limitation is that the Stelo lacks the urgent low glucose alarms that are standard on the G7, a regulatory requirement for the OTC category. This means it is not suitable for people at risk of severe hypoglycemia or those on insulin therapy. The Stelo also does not integrate with insulin pumps or smartwatches in the same way the G7 does, and its data-sharing features are more limited.

What to look for

• Accuracy (MARD): Lower MARD percentages indicate better agreement with lab glucose values. Look for sensors with MARD below 10 percent for reliable treatment decisions.
• Sensor wear time: Longer wear periods (14 days, 15 days, or 6 months) mean fewer sensor changes and lower annual supply costs.
• Warm-up time: Faster warm-up (30 minutes or less) reduces the gap between sensor application and usable readings.
• Integration with devices: Check if the sensor works with your smartphone, smartwatch, and insulin pump. More integration options improve convenience.
• Prescription requirement: Some CGMs require a prescription, while others like the Dexcom Stelo are available over the counter. Choose based on your access and needs.
• Alarm and alert features: Urgent low glucose alarms are critical for insulin users. OTC devices may omit these for safety reasons.
• Insertion and comfort: Consider the applicator design, sensor size, and adhesive quality. Implantable options avoid daily adhesive but require a procedure.
• Insurance coverage: Verify coverage for prescription sensors, as out-of-pocket costs vary widely. OTC sensors are paid for entirely by the user.

The verdict

For most people managing diabetes, the Dexcom G7 is the best overall choice because it combines the highest accuracy with the fastest warm-up and the widest device compatibility. If your priority is minimizing cost and sensor changes, the Abbott Freestyle Libre 3 offers excellent value with its 14-day wear and thin profile. Medtronic Guardian 4 is the only option for full closed-loop insulin delivery with the MiniMed 780G system. The Eversense E3 solves the problem of frequent sensor changes for those with adhesive issues or needle fatigue. And the Dexcom Stelo opens CGM access to non-diabetics and non-insulin users without a prescription. Choose the one that matches your specific glucose management needs and lifestyle.